Molecular Characterization of Peritoneal Mesotheliomas.

Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I/II clinical trial.

Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.

Treatment of Platinum Nonresponsive Metastatic Malignant Peritoneal Mesothelioma With Combination Chemoimmunotherapy.

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab.

The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study.

Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma.

The therapeutic implications of the genomic analysis of malignant pleural mesothelioma.

Inherited Rare, Deleterious Variants in ATM Increase Lung Adenocarcinoma Risk.

COVID-19 in patients with lung cancer.

Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas.

A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma.

Workshop summary: Potential usefulness and feasibility of a US National Mesothelioma Registry.

V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.

Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations.